+ Watch MD
on My Watchlist
The Company provides neonatal, maternal fetal and other pediatric subspecialty physician services in 32 states and Puerto Rico.
Mednax depends heavily on Medicaid reimbursements. Over the next few years Medicaid will decrease reimbursements to physicians in order to cut the cost of Healthcare. Mednax has billing and collections down to a science. They are ahead of the curve in terms of electronic medical record and is already billing for every cent they can. Mednax is primarily a large neonatology group. NICUs cost Medicaid a large portion of their budget. It will be the first one to be slashed. Watch for this. Once Medicaid reimbursements drop the stock will plummet.
Five star stock bouncing off a recent drop.
Strong Fundamentals with strong support levels. Healthcare industr which should hold up well in spite of the economy.
Good Caps, Low Relative PE, Earnings OK ... weekly bottom fishing expedition :-)
Medical still needed in rough times, MFI.
solid earning potential esp with increased revenues from lucrtative field of anesthesiology. Do you know that the cost of administering one spinal/epidural injection is more than a thousand dollars!
Phenomenal returns on capital and free cash flow. Competitive position looks good, considering they staff 1/6th of the NICUs in the U.S. and it's a limited market to begin with. I have trouble believing that lower birth rates are here to stay... up until recently the 2000's had seen the highest rates in 40 years.
i rate it so i can remember it
2.53B market cap, 15.4 price/earnings, negligible debt/equity, all very attractive. Throw in the niche market of pediatric/neonatal/anesthesia services and growing market for intensivists, plus the greater than 100% return on capital, very attractive indeed.
Least financial rewarding sector in health care (pediatrics), customers have none of their own money, payer mix is 50% Medicaid. Ponzi scheme. Management offering $1M sign-on bonuses to pediatric cardiologists in St. Petersburg, unsupported by fundamentals.
While missing revenue by a mear .01 percent, shareholders were not amused and trashed this stock by 14%. I believe this is an overreaction and have bought in accordingly.
I am always looking for good medical sector picks to start the recovery with, when it comes. This one seems to be weathering the slowdown rather nicely, which is definately a plus for me. I can pick it now and it won't pound my score so bad while the upcoming recession works it's way out. Other good healthcare picks that I have aren't doing that.
I SHALL BUY THIS SOON AS I HAVE A FEELING OF GOOD BUSINESS RESULTS BY END OF THIS YEAR.
Can anyone argue one of the most heavily invested areas in health care will be protecting our most fragile children, preemies? They do it the best of anyone, and this is one area that will not go away.
Revenues are rising but there is still room to grow. Future seen as positive by most analysts.
stock has great potential in a very specific area of natal care
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions